Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2022 Jul 18;10(7):1450.
doi: 10.3390/microorganisms10071450.

Viral Vector Vaccine Development and Application during the COVID-19 Pandemic

Shaofeng Deng  1   2 , Hui Liang  3 , Pin Chen  4   5 , Yuwan Li  3   6 , Zhaoyao Li  3   6 , Shuangqi Fan  3   6 , Keke Wu  3   6 , Xiaowen Li  3   6 , Wenxian Chen  3   6 , Yuwei Qin  3   6 , Lin Yi  3   6 , Jinding Chen  3   6
Affiliations
Review

Viral Vector Vaccine Development and Application during the COVID-19 Pandemic

Shaofeng Deng et al. Microorganisms. .

Abstract

With the accumulation of mutations in SARS-CoV-2 and the continuous emergence of new variants, the importance of developing safer and effective vaccines has become more prominent in combating the COVID-19 pandemic. Both traditional and genetically engineered vaccines have contributed to the prevention and control of the pandemic. However, in recent years, the trend of vaccination research has gradually transitioned from traditional to genetically engineered vaccines, with the development of viral vector vaccines attracting increasing attention. Viral vector vaccines have several unique advantages compared to other vaccine platforms. The spread of Omicron has also made the development of intranasal viral vector vaccines more urgent, as the infection site of Omicron is more prominent in the upper respiratory tract. Therefore, the present review focuses on the development of viral vector vaccines and their application during the COVID-19 pandemic.

Keywords: COVID-19; SARS-CoV-2; viral vector vaccine.

PubMed Disclaimer

Conflict of interest statement

The authors declare no conflict of interest.

Figures

Figure 1
Figure 1
Different platforms used for development of vaccines.
Figure 2
Figure 2
Mechanism of viral vector vaccines induce specific cellular and antibody responses.
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

    1. WHO COVID-19 Vaccine Tracker and Landscape. [(accessed on 25 May 2022)]. Available online: https://www.who.int/publications/m/item/draft-landscape-of-covid-19-cand....
    1. Humphreys I.R., Sebastian S. Novel viral vectors in infectious diseases. Immunology. 2018;153:1–9. doi: 10.1111/imm.12829. - DOI - PMC - PubMed
    1. Baron M.D., Iqbal M., Nair V. Recent advances in viral vectors in veterinary vaccinology. Curr. Opin. Virol. 2018;29:1–7. doi: 10.1016/j.coviro.2018.02.002. - DOI - PubMed
    1. Abbink P., Larocca R.A., De La Barrera R.A., Bricault C.A., Moseley E.T., Boyd M., Kirilova M., Li Z., Ng’ang’a D., Nanayakkara O., et al. Protective efficacy of multiple vaccine platforms against Zika virus challenge in rhesus monkeys. Science. 2016;353:1129–1132. doi: 10.1126/science.aah6157. - DOI - PMC - PubMed
    1. Barouch D.H., Tomaka F.L., Wegmann F., Stieh D.J., Alter G., Robb M.L., Michael N.L., Peter L., Nkolola J.P., Borducchi E.N., et al. Evaluation of a mosaic HIV-1 vaccine in a multicentre, randomised, double-blind, placebo-controlled, phase 1/2a clinical trial (APPROACH) and in rhesus monkeys (NHP 13-19) Lancet. 2018;392:232–243. doi: 10.1016/S0140-6736(18)31364-3. - DOI - PMC - PubMed

LinkOut - more resources